Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | ![]() The Phaeo and Para Cancer Charity of the UK and ARJUNA Therapeutics Announce Their CollaborationJo Williamson, Chairman of the Phaeo and Para Cancer Charity and Chief Patient Representative of Arjuna said, "This is an exciting development for us. ARJUNA's drug showed excellent efficacy in a pre-clinical model of SDH-B mutant paraganglionoma and we're delighted to help support ongoing preclinical development of this potential treatment to given hope to phaeo/para patients and their families as well as potentially other groups of cancer patients". Ross Breckenridge PhD FRCP, CEO of ARJUNA Therapeutics said, "ARJUNA is very grateful for the support of the Phaeo and Para Charity in this potential indication for our lead drug Ag5. Paraganglionoma/ The Phaeo and Para Cancer Charity of the UK was founded to research and develop treatments for this group of rare cancers. ARJUNA Therapeutics is developing an entirely novel platform of small molecules that cross the blood-brain- More information about the company can be found at http://www.arjunatherapeutics.com End
|
|